Article
Retrospective Analysis of Treatment Pathways in Patients With BRAFV600E-mutant Metastatic Colorectal Carcinoma - MORSECRC.
Anticancer research - 1 Oct 2022
Gerger Armin, Eisterer Wolfgang, Fuxius Stefan, Bastian Sara, Koeberle Dieter, Welslau Manfred, Sanoyan Dilara Akhoundova, Maas Christian, Uhlig Jens, Fenchel Klaus, Greil Richard, VON DER Heyde Eyck, Agocs Gaëlle Rhyner, Weide Rudolf, Schwager Monika, Reichenbach Frank, Modest Dominik Paul, Fritsch Ralph
Abstract excerpt
BACKGROUND/AIM: Metastatic colorectal cancer (mCRC) is a heterogeneous disease with distinct molecular subtypes. The BRAFV600E-mutation found in approximately 8-12% of mCRC patients is associated with poor prognosis. Guideline recommendations for this population are mostly based on small cohorts due to lack of clinical data. This retrospective analysis was designed to evaluate (approved) therapeutic approaches...
Topics
- Antibodies, Monoclonal
- Antineoplastic Combined Chemotherapy Protocols
- Carbamates
- Cetuximab
- Colorectal Neoplasms
- Female
- Humans
- Male
- Microsatellite Instability